|
Two-Day Program
Sept. 29–30, 2021
|
|
|
Wednesday, Sept. 29, 2021
*All times are Eastern Daylight Time.
|
| Opening Remarks |
| Time: |
10:00 – 10:10 a.m. EDT
|
Length:
|
10 minutes
|
Organizer:
|
Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center |
|
Session I: “Omics” Technologies and the Surfaceome
|
|
Time:
|
10:10 –11:40 a.m. EDT
|
|
Length:
|
90 minutes
|
|
Moderator:
|
Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center |
|
10:10 a.m.
|
Vaccinating against neoantigens induced in tumors and pathogen infected cells
Eli Gilboa, PhD – University of Miami
|
|
10:40 a.m.
|
Development and engineering of human sialidase for degradation of immunosuppressive cell surface sialoglycans to treat cancer
Li Peng, PhD – Palleon Pharmaceuticals
|
|
11:10 a.m.
|
Neoantigen Discovery and Targeting
Robert D. Schreiber, PhD –Washington University School of Medicine
|
|
11:40 a.m.
|
Break
|
|
Session II: Tumor Neoantigens
|
|
Time:
|
11:50 a.m.– 1:20 p.m. EDT
|
|
Length:
|
90 minutes
|
|
Moderator:
|
Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center
|
|
11:50 a.m.
|
Canonical Neoantigens
Beatriz M. Carreno, PhD – University of Pennsylvania
|
|
12:20 p.m.
|
Non-Canonical Tumor-Specific Antigens
Claude Perreault, MD – University of Montreal
|
|
12:50 a.m.
|
RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets
Yi Xing, PhD – Children's Hospital of Philadelphia
|
|
Break
|
|
Time:
|
1:20 –1:40 p.m. EDT
|
|
Session III: Oral Abstract Presentations
|
|
Time:
|
1:40 – 2:40 p.m. EDT
|
|
Length:
|
60 minutes
|
|
Moderator:
|
Avery D. Posey Jr., PhD – University of Pennsylvania School of Medicine
|
|
1:40 p.m.
|
Identification of novel, tumor specific pHLA targets recognized by TILs from CPI responders in a high-throughput, high-diversity pHLA library screening platform
Hans-Peter Gerber, PhD – 3T Biosciences
|
|
1:55 p.m.
|
Protein citrullination as a source of cancer neoantigens
Hiroyuki Katayama, PhD –The University of Texas MD Anderson Cancer Center
|
|
2:10 p.m.
|
Mapping the high-risk Multiple Myeloma cell surface proteome identifies T-cell inhibitory receptors for immune targeting
Fabiana Perna, MD, PhD – Indiana University School of Medicine
|
|
2:25 p.m.
|
The extracellular vesicle surfaceome is enriched in tumor antigens and conveys an immune-signature in lung cancer
Jody Vykoukal, PhD – The University of Texas MD Anderson Cancer Center
|
|
Keynote
|
|
Time:
|
2:40 – 3:15 p.m. EDT
|
|
Length:
|
35 minutes
|
|
2:40 p.m.
|
Keynote
Carl H. June, PhD – University of Pennsylvania
|
Session IV: Extracellular Vesicles |
|
Time:
|
3:15 – 4:15 p.m. EDT
|
|
Length:
|
60 minutes
|
|
Moderator:
|
Avery D. Posey Jr., PhD – University of Pennsylvania School of Medicine
|
|
3:15 p.m.
|
Mining the Cancer Cell surfaceome
Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center
|
|
3:45 p.m.
|
The Immunopeptidome of extracellular vesicles
Simon J. Powis, PhD – University of St. Andrews
|
|
4:15 p.m.
|
Break
|
Session V: Post-Translational Modifications |
|
Time:
|
4:20 – 5:20 p.m. EDT
|
|
4:20 p.m.
|
A Genetic Approach to Display and Dissect the Cancer-Associated Truncated O-Glycoprotein Epitome
Henrik Clausen, DDS, DSc – University of Copenhagen
|
|
4:50 p.m.
|
Tumor-specific Glycosylation and Antibody-Based Targeting
Richard D. Cummings, PhD – Harvard Medical School
|
|
Closing Remarks
|
|
Time:
|
5:20 – 5:30 p.m. EDT
|
|
Length:
|
10 minutes |
|
Organizer:
|
Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center
|
|
5:30 p.m.
|
Adjourn
|